SCHEMBL942900

SCHEMBL942900

CC(=O)NC(=S)NN=C(C)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.68
GAA P10253 3/20 0.68
NPSR1 Q6W5P4 1/20 0.68
MAPT P10636 3/20 0.64
POLB P06746 1/20 0.64
LMNA P02545 4/20 0.60
ALDH1A1 P00352 3/20 0.60
ATM Q13315 1/20 0.60
METTL3 Q86U44 1/20 0.60
ALOX12 P18054 3/20 0.59
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
NFKB1 P19838 2/20 0.57
NFKB2 Q00653 2/20 0.57
RELA Q04206 2/20 0.57
KDM4E B2RXH2 1/20 0.57
OPRK1 P41145 1/20 0.57
RAB9A P51151 5/20 0.56
NPC1 O15118 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27647467 0.83 ALDH1A1 (0.57) TDP1GAANPSR1MAPTLMNA
SCHEMBL7752872 0.82 MAPT (0.78) TDP1GAANPSR1MAPTPOLB
SCHEMBL12186262 0.82 MAPT (0.78) TDP1GAANPSR1MAPTPOLB
SCHEMBL27177997 0.82 MAPT (0.78) TDP1GAANPSR1MAPTPOLB
SCHEMBL759491 0.81 GAA (1.00) TDP1GAANPSR1MAPTPOLB
SCHEMBL15672271 0.81 GAA (1.00) TDP1GAANPSR1MAPTPOLB
SCHEMBL1563351 0.80 RAB9A (0.81) GAAMAPTPOLBLMNAALDH1A1
SCHEMBL5732784 0.80 RAB9A (0.81) GAAMAPTPOLBLMNAALDH1A1
SCHEMBL1563352 0.80 RAB9A (0.81) GAAMAPTPOLBLMNAALDH1A1
SCHEMBL27532371 0.79 RAB9A (0.78) GAAMAPTPOLBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20100240716-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-09-23 US disclosed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-7759371-B2 Thiadiazoline derivative Kyowa Hakko Kinn Co., Ltd. (JP) 2010-07-20 US disclosed
CN-100484928-C thiadiazoline derivatives KYOWA HAKKO KOGYO KK FUJI PHOT (JP) 2009-05-06 CN disclosed
US-7425636-B2 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-09-16 US disclosed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
CN-1617864-A thiadiazoline derivatives KYOWA HAKKO KOGYO KK (JP) 2005-05-18 CN disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 TDP1 1546/4885GAA 4130/4885NPSR1 3376/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B TDP1 1281/4885GAA 1882/4885NPSR1 4589/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 TDP1 1546/4885GAA 4130/4885NPSR1 3376/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B TDP1 1281/4885GAA 1882/4885NPSR1 4589/4885
US-20100240716-A1 THIADIAZOLINE DERIVATIVE BRWD1, WDR82, RB1 TDP1 1533/4885GAA 3801/4885NPSR1 3776/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 TDP1 1546/4885GAA 4130/4885NPSR1 3376/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B TDP1 1281/4885GAA 1882/4885NPSR1 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.